Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
暂无分享,去创建一个
K. Metzeler | K. Spiekermann | M. Subklewe | K. Hopfner | S. Kobold | F. Rataj | R. Mocikat | C. Krupka | M. Herrmann | B. Brauchle | N. Fenn | Katrin Deiser | Anetta Marcinek | Ana Ogrinc Wagner | Christina Krupka
[1] W. Rehrauer,et al. Fatal Myocarditis Following Treatment with the PD‐1 Inhibitor Nivolumab , 2018, Journal of forensic sciences.
[2] H. Dolstra,et al. Immune checkpoint molecules in acute myeloid leukaemia: managing the double‐edged sword , 2018, British journal of haematology.
[3] D. Weisenburger,et al. Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status , 2017, Haematologica.
[4] A. Iyer,et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..
[5] R. Rosell,et al. The combination of checkpoint immunotherapy and targeted therapy in cancer. , 2017, Annals of translational medicine.
[6] M. Subklewe,et al. Recent developments in immunotherapy of acute myeloid leukemia , 2017, Journal of Hematology & Oncology.
[7] P. Sharma,et al. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. , 2017 .
[8] C. Bocsan,et al. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies , 2017, OncoTargets and therapy.
[9] C. Hourigan,et al. Measurable residual disease testing in acute myeloid leukaemia , 2017, Leukemia.
[10] D. Schadendorf,et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Rudin,et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Christopher G. Kanakry,et al. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. , 2017, Current drug targets.
[13] P. Ruf,et al. Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition , 2016, Oncotarget.
[14] D. Porter,et al. CAR T‐cells merge into the fast lane of cancer care , 2016, American journal of hematology.
[15] T. Knösel,et al. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab , 2015, Journal of Hematology & Oncology.
[16] S. Endres,et al. Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. , 2015, Journal of the National Cancer Institute.
[17] R. Walter,et al. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330 , 2015, Blood Cancer Journal.
[18] M. Subklewe,et al. Immunotherapy for Acute Myeloid Leukemia. , 2015, Seminars in hematology.
[19] M. Atkins,et al. Toxicities of Immunotherapy for the Practitioner. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] David C. Smith,et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Sanford. Blinatumomab: First Global Approval , 2015, Drugs.
[22] Michael Loran Dustin. The Immunological Synapse , 2014, Cancer Immunology Research.
[23] S. Fröhling,et al. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia , 2014, Leukemia.
[24] C. Craddock,et al. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia , 2014, Annals of Hematology.
[25] G. Fey,et al. T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell , 2014, Oncotarget.
[26] E. Estey,et al. The past and future of CD33 as therapeutic target in acute myeloid leukemia. , 2014, Blood reviews.
[27] G. Ehninger,et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.
[28] A. Henn,et al. Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia , 2014, Molecular Cancer Therapeutics.
[29] C. Blank,et al. Interferon‐induced programmed death‐ligand 1 (PD‐L1/B7‐H1) expression increases on human acute myeloid leukemia blast cells during treatment , 2014, European journal of haematology.
[30] R. Kischel,et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. , 2014, Blood.
[31] W. Hiddemann,et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. , 2014, Blood.
[32] R. Meijers,et al. Optimization of protein purification and characterization using Thermofluor screens. , 2013, Protein expression and purification.
[33] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[34] D. Teachey,et al. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-4023. , 2016, Blood.
[35] A. Mackensen,et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct , 2013, Leukemia.
[36] John E. Ladbury,et al. Structure and Interactions of the Human Programmed Cell Death 1 Receptor* , 2013, The Journal of Biological Chemistry.
[37] A. Bennaceur-Griscelli,et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. , 2011, Blood.
[38] A. Korman,et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. , 2011, Cancer research.
[39] S. Eschrich,et al. Abstract 5111: Integrative phospho-proteomic and genomic analyses identify AXL as a potential biomarker and therapeutic target for NRAS-mutated melanoma , 2011 .
[40] B. Quesnel,et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors , 2010, Cancer Immunology, Immunotherapy.
[41] S. Asano,et al. An evidence for adhesion-mediated acquisition of acute myeloid leukemic stem cell-like immaturities. , 2010, Biochemical and biophysical research communications.
[42] E. Hoster,et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] P. Bugelski,et al. Monoclonal antibody-induced cytokine-release syndrome , 2009, Expert review of clinical immunology.
[44] W. Hiddemann,et al. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia , 2008, British journal of haematology.
[45] Manmohan J. Singh,et al. Endotoxin limits in formulations for preclinical research. , 2008, Journal of pharmaceutical sciences.
[46] H. Ljunggren,et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. , 2008, Blood.
[47] D. Y. Lin,et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors , 2008, Proceedings of the National Academy of Sciences.
[48] P. Kufer,et al. Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class , 2007 .
[49] R. Kimmig,et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. , 2006, Molecular immunology.
[50] T. Lister,et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.
[51] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[52] P. Hoffmann,et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct , 2005, International journal of cancer.
[53] P. Romeo,et al. Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein , 2003, Nature Medicine.
[54] P. Hoffmann,et al. Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody , 2002, International journal of cancer.
[55] B. Dörken,et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. , 2000, Blood.
[56] W. Hiddemann,et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. , 1999, Blood.
[57] W. Anderson,et al. Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. , 1997, Journal of immunological methods.
[58] A. Plückthun,et al. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. , 1997, Journal of immunological methods.
[59] K. Goa,et al. Muromonab CD3 , 1996, Drugs.
[60] P. Crocker,et al. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. , 1995, Blood.
[61] D. Carson,et al. Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes. , 1985, Journal of immunology.
[62] K. Aonuma,et al. Immune checkpoint inhibitor-related myocarditis , 2018, Japanese journal of clinical oncology.
[63] W. Hiddemann,et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism , 2016, Leukemia.
[64] W. Hiddemann,et al. Current strategies in immunotherapy for acute myeloid leukemia. , 2013, Immunotherapy.
[65] R. Bouabdallah,et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group , 2007, Leukemia.